What is William Blair's Estimate for Biodesix Q1 Earnings?

Biodesix, Inc. (NASDAQ:BDSX - Free Report) - Equities researchers at William Blair issued their Q1 2026 EPS estimates for shares of Biodesix in a report released on Tuesday, March 4th. William Blair analyst A. Brackmann forecasts that the company will post earnings per share of ($0.05) for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Biodesix's current full-year earnings is ($0.35) per share. William Blair also issued estimates for Biodesix's Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.14) EPS.

Biodesix Trading Up 1.4 %

Biodesix stock traded up $0.01 during trading on Wednesday, hitting $0.86. The company had a trading volume of 348,600 shares, compared to its average volume of 510,352. Biodesix has a 1-year low of $0.64 and a 1-year high of $2.04. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30. The company's 50 day simple moving average is $1.08 and its 200-day simple moving average is $1.40. The stock has a market cap of $125.42 million, a price-to-earnings ratio of -2.21 and a beta of 1.10.

Biodesix (NASDAQ:BDSX - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. The firm had revenue of $20.43 million during the quarter, compared to the consensus estimate of $19.92 million.

Remove Ads

Hedge Funds Weigh In On Biodesix

Several institutional investors have recently modified their holdings of BDSX. Wilmington Savings Fund Society FSB acquired a new position in shares of Biodesix in the third quarter worth $10,849,000. Samjo Management LLC acquired a new position in shares of Biodesix in the fourth quarter worth $3,790,000. Susquehanna International Group LLP grew its stake in shares of Biodesix by 769.8% in the fourth quarter. Susquehanna International Group LLP now owns 1,115,748 shares of the company's stock worth $1,707,000 after acquiring an additional 987,475 shares in the last quarter. Silverarc Capital Management LLC grew its stake in shares of Biodesix by 21.7% in the fourth quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company's stock worth $6,628,000 after acquiring an additional 771,187 shares in the last quarter. Finally, AIGH Capital Management LLC grew its stake in shares of Biodesix by 8.8% during the fourth quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company's stock worth $9,455,000 after purchasing an additional 500,000 shares in the last quarter. Institutional investors and hedge funds own 20.96% of the company's stock.

Insiders Place Their Bets

In other Biodesix news, CEO Scott Hutton sold 83,660 shares of the business's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $76,967.20. Following the completion of the transaction, the chief executive officer now owns 701,947 shares in the company, valued at $645,791.24. The trade was a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders sold a total of 128,702 shares of company stock worth $118,406 over the last 90 days. Corporate insiders own 69.20% of the company's stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.